{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:33:59Z","timestamp":1791920039540,"version":"4.3.4"},"reference-count":74,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.phrs.2019.04.018","type":"journal-article","created":{"date-parts":[[2019,4,17]],"date-time":"2019-04-17T13:20:46Z","timestamp":1555507246000},"page":"104234","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":167,"special_numbering":"C","title":["Drugs and hepatic transporters: A review"],"prefix":"10.1016","volume":"154","author":[{"given":"Alexander","family":"Jetter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd A.","family":"Kullak-Ublick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.phrs.2019.04.018_bib0005","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1152\/ajplegacy.1976.231.3.734","article-title":"Uptake of bile acids by perfused rat liver","volume":"231","author":"Reichen","year":"1976","journal-title":"Am. J. Physiol."},{"issue":"23","key":"10.1016\/j.phrs.2019.04.018_bib0010","doi-asserted-by":"crossref","first-page":"10629","DOI":"10.1073\/pnas.88.23.10629","article-title":"Functional expression cloning and characterization of the hepatocyte Na+\/bile acid cotransport system","volume":"88","author":"Hagenbuch","year":"1991","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.phrs.2019.04.018_bib0015","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1172\/JCI117091","article-title":"Molecular cloning, chromosomal localization, and functional characterization of a human liver Na+\/bile acid cotransporter","volume":"93","author":"Hagenbuch","year":"1994","journal-title":"J. Clin. Invest."},{"issue":"8","key":"10.1016\/j.phrs.2019.04.018_bib0020","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/bdd.1861","article-title":"Quantitative assessment of the contribution of sodium-dependent taurocholate co-transporting polypeptide (NTCP) to the hepatic uptake of rosuvastatin, pitavastatin and fluvastatin","volume":"34","author":"Bi","year":"2013","journal-title":"Biopharm. Drug Dispos."},{"issue":"4","key":"10.1016\/j.phrs.2019.04.018_bib0025","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1053\/j.gastro.2013.12.024","article-title":"Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes","volume":"146","author":"Ni","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2019.04.018_bib0030","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.00049","article-title":"Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus","volume":"1","author":"Yan","year":"2012","journal-title":"Elife"},{"issue":"4","key":"10.1016\/j.phrs.2019.04.018_bib0035","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/0016-5085(95)90588-X","article-title":"Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver","volume":"109","author":"Kullak-Ublick","year":"1995","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.phrs.2019.04.018_bib0040","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1007\/s00424-014-1596-x","article-title":"Differential cellular expression of organic anion transporting peptides OATP1A2 and OATP2B1 in the human retina and brain: implications for carrier-mediated transport of neuropeptides and neurosteriods in the CNS","volume":"467","author":"Gao","year":"2015","journal-title":"Pflugers Arch."},{"issue":"5","key":"10.1016\/j.phrs.2019.04.018_bib0045","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2217\/14622416.9.5.597","article-title":"Pharmacogenetics of OATP (SLC21\/SLCO), OAT and OCT (SLC22) and PEPT (SLC15) transporters in the intestine, liver and kidney","volume":"9","author":"Zair","year":"2008","journal-title":"Pharmacogenomics"},{"issue":"2","key":"10.1016\/j.phrs.2019.04.018_bib0050","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1053\/gast.2001.21176","article-title":"Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver","volume":"120","author":"Kullak-Ublick","year":"2001","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.phrs.2019.04.018_bib0055","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1476-5381.2009.00430.x","article-title":"Impact of OATP transporters on pharmacokinetics","volume":"158","author":"Kalliokoski","year":"2009","journal-title":"Br. J. Pharmacol."},{"issue":"6","key":"10.1016\/j.phrs.2019.04.018_bib0060","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.clpt.2006.09.003","article-title":"Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance","volume":"80","author":"Neuvonen","year":"2006","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.phrs.2019.04.018_bib0065","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1124\/pr.110.002857","article-title":"Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake","volume":"63","author":"Niemi","year":"2011","journal-title":"Pharmacol. Rev."},{"issue":"1","key":"10.1016\/j.phrs.2019.04.018_bib0070","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1124\/jpet.104.068536","volume":"311","author":"Shitara","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.phrs.2019.04.018_bib0075","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1124\/jpet.106.103390","article-title":"Vectorial transport of enalapril by Oatp1a1\/Mrp2 and OATP1B1 and OATP1B3\/MRP2 in rat and human livers","volume":"318","author":"Liu","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"8","key":"10.1016\/j.phrs.2019.04.018_bib0080","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa0801936","article-title":"SLCO1B1 variants and statin-induced myopathy--a genomewide study","volume":"359","author":"Search Collaborative Group","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.phrs.2019.04.018_bib0085","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1053\/jhep.2002.34133","article-title":"Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver","volume":"36","author":"Vavricka","year":"2002","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.phrs.2019.04.018_bib0090","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1124\/jpet.115.227546","article-title":"Octreotide inhibits the bilirubin carriers organic anion transporting polypeptides 1B1 and 1B3 and the multidrug resistance-associated protein 2","volume":"355","author":"Visentin","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"3","key":"10.1016\/j.phrs.2019.04.018_bib0095","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1515\/dmdi-2013-0062","article-title":"Role of OATP-1B1 and\/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitors","volume":"29","author":"Khurana","year":"2014","journal-title":"Drug Metabol. Drug Interact."},{"issue":"4","key":"10.1016\/j.phrs.2019.04.018_bib0100","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1515\/dmdi-2014-0014","article-title":"Inhibition of OATP-1B1 and OATP-1B3 by tyrosine kinase inhibitors","volume":"29","author":"Khurana","year":"2014","journal-title":"Drug Metabol. Drug Interact."},{"issue":"11","key":"10.1016\/j.phrs.2019.04.018_bib0105","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1124\/dmd.114.059097","article-title":"Selective inhibition of human solute carrier transporters by multikinase inhibitors","volume":"42","author":"Johnston","year":"2014","journal-title":"Drug Metab. Dispos."},{"issue":"2","key":"10.1016\/j.phrs.2019.04.018_bib0110","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1172\/JCI59526","article-title":"Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver","volume":"122","author":"van de Steeg","year":"2012","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.phrs.2019.04.018_bib0115","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1124\/dmd.116.072264","article-title":"Organic anion transporter 2: an enigmatic human solute carrier","volume":"45","author":"Shen","year":"2017","journal-title":"Drug Metab. Dispos."},{"issue":"1","key":"10.1016\/j.phrs.2019.04.018_bib0120","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.dmpk.2016.09.004","article-title":"Human organic anion transporter 2 is an entecavir, but not tenofovir, transporter","volume":"32","author":"Furihata","year":"2017","journal-title":"Drug Metab. Pharmacokinet."},{"issue":"3","key":"10.1016\/j.phrs.2019.04.018_bib0125","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1124\/jpet.117.245951","article-title":"Organic anion transporter 2 mediates hepatic uptake of tolbutamide, a CYP2C9 probe drug","volume":"364","author":"Bi","year":"2018","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"3","key":"10.1016\/j.phrs.2019.04.018_bib0130","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00228-004-0754-z","article-title":"Cytochrome P450 2C9 phenotyping using low-dose tolbutamide","volume":"60","author":"Jetter","year":"2004","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.phrs.2019.04.018_bib0135","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/tpj.2015.55","article-title":"Variability in hepatic expression of organic anion transporter 7\/SLC22A9, a novel pravastatin uptake transporter: impact of genetic and regulatory factors","volume":"16","author":"Emami Riedmaier","year":"2016","journal-title":"Pharmacogen. J."},{"key":"10.1016\/j.phrs.2019.04.018_bib0140","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/978-3-642-14541-4_3","article-title":"Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy","volume":"201","author":"Nies","year":"2011","journal-title":"Handb. Exp. Pharmacol."},{"issue":"201","key":"10.1016\/j.phrs.2019.04.018_bib0145","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/978-3-642-14541-4_8","article-title":"Multidrug resistance proteins (MRPs, ABCCs): importance for pathophysiology and drug therapy","author":"Keppler","year":"2011","journal-title":"Handb. Exp. Pharmacol."},{"issue":"3","key":"10.1016\/j.phrs.2019.04.018_bib0150","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1152\/physrev.00035.2005","article-title":"Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins","volume":"86","author":"Deeley","year":"2006","journal-title":"Physiol. Rev."},{"issue":"3","key":"10.1016\/j.phrs.2019.04.018_bib0155","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1054\/bjoc.2000.1262","article-title":"Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export","volume":"83","author":"Evers","year":"2000","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.phrs.2019.04.018_bib0160","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1124\/jpet.106.110106","article-title":"Evaluation of the role of multidrug resistance-associated protein (Mrp) 3 and Mrp4 in hepatic basolateral excretion of sulfate and glucuronide metabolites of acetaminophen, 4-methylumbelliferone, and harmol in Abcc3-\/- and Abcc4-\/- mice","volume":"319","author":"Zamek-Gliszczynski","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"9","key":"10.1016\/j.phrs.2019.04.018_bib0165","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1007\/s11095-013-1007-6","article-title":"Metabolism and disposition of acetaminophen: recent advances in relation to hepatotoxicity and diagnosis","volume":"30","author":"McGill","year":"2013","journal-title":"Pharm. Res."},{"issue":"2","key":"10.1016\/j.phrs.2019.04.018_bib0170","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1124\/mol.107.035592","article-title":"Multidrug resistance proteins 2 and 3 provide alternative routes for hepatic excretion of morphine-glucuronides","volume":"72","author":"van de Wetering","year":"2007","journal-title":"Mol. Pharmacol."},{"issue":"3","key":"10.1016\/j.phrs.2019.04.018_bib0175","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3109\/03602530903492004","article-title":"Role of the bile salt export pump, BSEP, in acquired forms of cholestasis","volume":"42","author":"Stieger","year":"2010","journal-title":"Drug Metab. Rev."},{"issue":"9","key":"10.1016\/j.phrs.2019.04.018_bib0180","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1016\/j.xphs.2017.04.053","article-title":"Effect of liver disease on hepatic transporter expression and function","volume":"106","author":"Thakkar","year":"2017","journal-title":"J. Pharm. Sci."},{"issue":"201","key":"10.1016\/j.phrs.2019.04.018_bib0185","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/978-3-642-14541-4_5","article-title":"The role of the sodium-taurocholate cotransporting polypeptide (NTCP) and of the bile salt export pump (BSEP) in physiology and pathophysiology of bile formation","author":"Stieger","year":"2011","journal-title":"Handb. Exp. Pharmacol."},{"issue":"8","key":"10.1016\/j.phrs.2019.04.018_bib0190","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1194\/jlr.R049437","article-title":"Key discoveries in bile acid chemistry and biology and their clinical applications: history of the last eight decades","volume":"55","author":"Hofmann","year":"2014","journal-title":"J. Lipid Res."},{"issue":"2","key":"10.1016\/j.phrs.2019.04.018_bib0195","first-page":"471","article-title":"Toxicity of bile acids on the electron transport chain of isolated rat liver mitochondria","volume":"19","author":"Kr\u00e4henb\u00fchl","year":"1994","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.phrs.2019.04.018_bib0200","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nrgastro.2011.22","article-title":"Mechanisms of drug-induced liver injury: from bedside to bench","volume":"8","author":"Tujios","year":"2011","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"Suppl. 1","key":"10.1016\/j.phrs.2019.04.018_bib0205","article-title":"Progressive familial intrahepatic cholestasis","volume":"36","author":"Jacquemin","year":"2012","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"issue":"2","key":"10.1016\/j.phrs.2019.04.018_bib0210","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1053\/j.gastro.2004.04.065","article-title":"Benign recurrent intrahepatic cholestasis type 2 is caused by mutations in ABCB11","volume":"127","author":"van Mil","year":"2004","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.phrs.2019.04.018_bib0215","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1136\/gutjnl-2016-313369","article-title":"Drug-induced liver injury: recent advances in diagnosis and risk assessment","volume":"66","author":"Kullak-Ublick","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.phrs.2019.04.018_bib0220","article-title":"Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: an international collaborative effort","author":"Church","year":"2018","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.phrs.2019.04.018_bib0225","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0026-895X(24)12255-9","article-title":"Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat","volume":"59","author":"Funk","year":"2001","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.phrs.2019.04.018_bib0230","first-page":"286","article-title":"The role of FXR in disorders of bile acid homeostasis","volume":"23","author":"Eloranta","year":"2008","journal-title":"Physiology (Bethesda)"},{"issue":"2","key":"10.1016\/j.phrs.2019.04.018_bib0235","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1124\/mol.117.111047","article-title":"Effects of farnesoid X receptor activation on arachidonic acid metabolism, NF-kB signaling, and hepatic inflammation","volume":"94","author":"Gai","year":"2018","journal-title":"Mol. Pharmacol."},{"issue":"3","key":"10.1016\/j.phrs.2019.04.018_bib0240","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.clinre.2015.12.017","article-title":"Bile acids in drug induced liver injury: key players and surrogate markers","volume":"40","author":"Schadt","year":"2016","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"issue":"16","key":"10.1016\/j.phrs.2019.04.018_bib0245","first-page":"3506","article-title":"Methotrexate is excreted into the bile by canalicular multispecific organic anion transporter in rats","volume":"57","author":"Masuda","year":"1997","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.phrs.2019.04.018_bib0250","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1111\/j.1476-5381.2011.01672.x","article-title":"Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells","volume":"165","author":"Fahrmayr","year":"2012","journal-title":"Br. J. Pharmacol."},{"issue":"5","key":"10.1016\/j.phrs.2019.04.018_bib0255","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s00424-006-0109-y","article-title":"The apical conjugate efflux pump ABCC2 (MRP2)","volume":"453","author":"Nies","year":"2007","journal-title":"Pflugers Arch."},{"issue":"1","key":"10.1016\/j.phrs.2019.04.018_bib0260","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1053\/jhep.2000.8263","article-title":"Mrp2 is essential for estradiol-17beta(beta-D-glucuronide)-induced cholestasis in rats","volume":"32","author":"Huang","year":"2000","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.phrs.2019.04.018_bib0265","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1208\/s12248-014-9668-6","article-title":"Role of the breast cancer resistance protein (BCRP\/ABCG2) in drug transport--an update","volume":"17","author":"Mao","year":"2015","journal-title":"AAPS J."},{"issue":"6","key":"10.1016\/j.phrs.2019.04.018_bib0270","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2133\/dmpk.DMPK-12-RG-026","article-title":"Impact of genetic variation in breast cancer resistance protein (BCRP\/ABCG2) on sunitinib pharmacokinetics","volume":"27","author":"Mizuno","year":"2012","journal-title":"Drug Metab. Pharmacokinet."},{"issue":"8","key":"10.1016\/j.phrs.2019.04.018_bib0275","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1124\/dmd.112.050286","article-title":"Effect of P-glycoprotein and breast cancer resistance protein inhibition on the pharmacokinetics of sunitinib in rats","volume":"41","author":"Kunimatsu","year":"2013","journal-title":"Drug Metab. Dispos."},{"issue":"1","key":"10.1016\/j.phrs.2019.04.018_bib0280","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.canlet.2009.01.027","article-title":"Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2","volume":"279","author":"Dai","year":"2009","journal-title":"Cancer Lett."},{"issue":"201","key":"10.1016\/j.phrs.2019.04.018_bib0285","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/978-3-642-14541-4_6","article-title":"P-glycoprotein: tissue distribution, substrates, and functional consequences of genetic variations","author":"Cascorbi","year":"2011","journal-title":"Handb. Exp. Pharmacol."},{"issue":"7","key":"10.1016\/j.phrs.2019.04.018_bib0290","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s40262-015-0267-1","article-title":"Impact of genetic polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on drug disposition and potential clinical implications: update of the literature","volume":"54","author":"Wolking","year":"2015","journal-title":"Clin. Pharmacokinet."},{"issue":"12","key":"10.1016\/j.phrs.2019.04.018_bib0295","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1097\/01.fpc.0000230113.03710.34","article-title":"In-vitro transport characteristics discriminate wild-type ABCB1 (MDR1) from ALA893SER and ALA893THR polymorphisms","volume":"16","author":"Schaefer","year":"2006","journal-title":"Pharmacogenet. Genomics"},{"issue":"1","key":"10.1016\/j.phrs.2019.04.018_bib0300","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/sj.clpt.6100452","article-title":"Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients","volume":"84","author":"Wyen","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.phrs.2019.04.018_bib0305","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/01.fpc.0000230418.28091.76","article-title":"Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury","volume":"17","author":"Lang","year":"2007","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.phrs.2019.04.018_bib0310","doi-asserted-by":"crossref","first-page":"4242","DOI":"10.2741\/3526","article-title":"Liver diseases related to MDR3 (ABCB4) gene deficiency","volume":"14","author":"Gonzales","year":"2009","journal-title":"Front. Biosci. (Landmark Ed.)"},{"issue":"3","key":"10.1016\/j.phrs.2019.04.018_bib0315","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/hep.20159","article-title":"BSEP and MDR3 haplotype structure in healthy Caucasians, primary biliary cirrhosis and primary sclerosing cholangitis","volume":"39","author":"Pauli-Magnus","year":"2004","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.phrs.2019.04.018_bib0320","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1124\/mol.116.103390","article-title":"Role of multidrug resistance protein 3 in antifungal-induced cholestasis","volume":"90","author":"Mahdi","year":"2016","journal-title":"Mol. Pharmacol."},{"issue":"5","key":"10.1016\/j.phrs.2019.04.018_bib0325","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1021\/acs.chemrestox.7b00048","article-title":"Evaluating the role of multidrug resistance protein 3 (MDR3) inhibition in predicting drug-induced liver injury using 125 pharmaceuticals","volume":"30","author":"Aleo","year":"2017","journal-title":"Chem. Res. Toxicol."},{"issue":"7","key":"10.1016\/j.phrs.2019.04.018_bib0330","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.bbalip.2009.02.008","article-title":"P4 ATPases - lipid flippases and their role in disease","volume":"1791","author":"Folmer","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"issue":"4","key":"10.1016\/j.phrs.2019.04.018_bib0335","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.cld.2018.06.003","article-title":"Progressive familial intrahepatic cholestasis","volume":"22","author":"Bull","year":"2018","journal-title":"Clin. Liver Dis."},{"issue":"2","key":"10.1016\/j.phrs.2019.04.018_bib0340","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1089-3261(05)70114-8","article-title":"Mechanisms of cholestasis","volume":"4","author":"Kullak-Ublick","year":"2000","journal-title":"Clin. Liver Dis."},{"issue":"4","key":"10.1016\/j.phrs.2019.04.018_bib0345","doi-asserted-by":"crossref","first-page":"499","DOI":"10.3109\/03602532.2011.602687","article-title":"Mammalian MATE (SLC47A) transport proteins: impact on efflux of endogenous substrates and xenobiotics","volume":"43","author":"Damme","year":"2011","journal-title":"Drug Metab. Rev."},{"issue":"50","key":"10.1016\/j.phrs.2019.04.018_bib0350","doi-asserted-by":"crossref","first-page":"17923","DOI":"10.1073\/pnas.0506483102","article-title":"A human transporter protein that mediates the final excretion step for toxic organic cations","volume":"102","author":"Otsuka","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.phrs.2019.04.018_bib0355","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/clpt.2013.74","article-title":"Emerging transporters of clinical importance: an update from the International Transporter Consortium","volume":"94","author":"Hillgren","year":"2013","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2019.04.018_bib0360","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.2741\/3416","article-title":"OST alpha-OST beta: a key membrane transporter of bile acids and conjugated steroids","volume":"14","author":"Ballatori","year":"2009","journal-title":"Front. Biosci. (Landmark Ed.)"},{"issue":"4","key":"10.1016\/j.phrs.2019.04.018_bib0365","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1111\/liv.12558","article-title":"The organic solute transporters alpha and beta are induced by hypoxia in human hepatocytes","volume":"35","author":"Schaffner","year":"2015","journal-title":"Liver Int."},{"issue":"3","key":"10.1016\/j.phrs.2019.04.018_bib0370","doi-asserted-by":"crossref","first-page":"G476","DOI":"10.1152\/ajpgi.00430.2005","article-title":"The nuclear receptor for bile acids, FXR, transactivates human organic solute transporter-alpha and -beta genes","volume":"290","author":"Landrier","year":"2006","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661819300325?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661819300325?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:05:36Z","timestamp":1760911536000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661819300325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":74,"alternative-id":["S1043661819300325"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2019.04.018","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drugs and hepatic transporters: A review","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2019.04.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104234"}}